This website is for UK Healthcare Professionals.

Pomalidomide Accord Product Information

Pomalidomide Accord presentations

Capsule images not to scale

Presentations

Each presentation is available in packs of 21 hard capsules

size 4

1mg

14 mm

size 2

2mg

18 mm

size 2

3mg

18 mm

size 2

4mg

18 mm

Shelf life

3 years

Pomalidomide Accord Packaging

Launched November 2024

Pomalidomide Accord hard capsules

Offering the same range of strengths and for the same indications as Imnovid®*5, 6

Differentiated packaging to aid dispensing

*Please refer to the prescribing information for the full list of indications

Lenalidomide Accord Product Information

Lenalidomide Accord presentations

Capsule images not to scale

Presentations

Each presentation is available in packs of 21 hard capsules

size 5

2.5mg

11.0 mm to 11.8 mm

size 5

5mg

11.0 mm to 11.8 mm

size 4

7.5mg

14.0 mm to 14.8 mm

size 3

10mg

15.4 mm to 16.2 mm

Shelf life

3 years

15-mg

size 2

15mg

17.4 mm to 18.2 mm

size 1

20mg

19.0 mm to 19.8 mm

size 0

25mg

21.0 mm to 21.8 mm

Lenalidomide Accord Packaging

Cross-perforated unit-dose blisters

Colour strength differentiated blisters

Data Matrix included on the blister

Launched January 2022

Lenalidomide Accord hard capsules

Offering the same range of strengths and for the same indications as Revlimid®*:3, 4

Differentiated packaging to aid dispensing

*Please refer to the prescribing information for the full list of indications
Launched February 2021

Thalidomide hard capsules

Offering the same strength and indication as thalidomide BMS*1,2

*Please refer to the prescribing information for the full list of indications

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Accord-UK Ltd on 01271 385257 or email [email protected].

References

  1. Accord-UK Ltd. Thalidomide Summary of Product Characteristics
  2. Bristol Myers Squibb Pharmaceuticals Ltd. Thalidomide BMS Summary of Product Characteristics
  3. Accord Healthcare Ltd. Lenalidomide Accord Summary of Product Characteristics
  4. Bristol Myers Squibb Pharmaceuticals Ltd. Revlimid® Summary of Product Characteristics
  5. Accord Healthcare Ltd. Pomalidomide Accord Summary of Product Characteristics
  6. Bristol Myers Squibb Pharmaceuticals Ltd. Imnovid® Summary of Product Characteristics

Please select

For UK Healthcare Professionals

If you are a UK healthcare professional and would like more information on thalidomide, lenalidomide or pomalidomide from Accord, please click here

Report Adverse Events

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.

Adverse events should also be reported to Accord-UK Ltd:

For the UK Public

For more information on thalidomide, lenalidomide or pomalidomide from Accord, please click below

Site intended for a UK audience only. UK-03777 June 2025